Zurück zu Projekte

17994.1 PFLS-LS

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Zusammenfassung

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Weitere Texte

Abstract

More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.

Beteiligte

Chad Brokopp

Wirtschaftspartner

Mabimmune Diagnostics AG Chad Brokopp Wagistrasse 13 8952 Schlieren ZH CH

Simon Hoerstrup

Kontaktperson

Simon_Philipp.Hoerstrup@usz.ch

Universität Zürich Simon Hoerstrup Rämistrasse 100 8091 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2015-07-31
Enddatum
2017-10-31
Bewilligte Gesamtkosten
CHF 671174.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%